Delcath Systems (DCTH) – Company Press Releases
-
Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
-
Delcath Systems Closes $7 Million Private Placement
-
Delcath Systems to Host Fourth Quarter and Full Year 2023 Results and Business Update Call
-
Delcath Systems Appoints Martha S. Rook as Chief Operating Officer
-
Delcath Systems Announces $7 Million Private Placement
-
Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Delcath Systems to Participate in Upcoming Investor Conferences
-
Delcath Systems Announces Healthcare Setting Locator for HEPZATO™ KIT (melphalan/Hepatic Delivery System)
-
Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Delcath Systems Receives Permanent J-Code (J9248) for HEPZATO™ (melphalan/Hepatic Delivery System) Effective April 1, 2024
-
Delcath Systems to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference
-
Delcath Systems Announces U.S. Launch and First Commercial Treatment Utilizing HEPZATO KIT™
-
Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Delcath Systems Announces Publication by Independent Investigators of a Retrospective Analysis of Quality of Life in the Journal Melanoma Research
-
Delcath Systems Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Delcath Systems Reports Third Quarter 2023 Results and Provides Business Update
-
Delcath Systems to Host Third Quarter 2023 Results Call
-
Delcath Systems Announces a Comparative Study of Chemosat and SIRT Published in the Journal Cancers
-
Delcath Systems to Participate in the Lytham Partners Fall 2023 Investor Conference
-
Delcath Systems to Participate at the Roth MKM 2023 Healthcare Opportunities Conference on October 12, 2023
-
Delcath Systems Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
A Retrospective Comparative Study of Chemosat and SIRT Presented at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Meeting
-
Delcath Systems to Participate at the H.C. Wainwright 25th Annual Investor Conference on September 12 and 13, 2023
-
Delcath Systems, Inc. Announces Additional $35 Million in Funding Tied to the FDA Approval of HEPZATO KIT™
-
Delcath Systems Announces an Independent Investigator Presentation at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Meeting
-
Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT™ for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma
-
Delcath Systems Reports Second Quarter 2023 Results and Provides Business Update
-
Delcath Systems to File Its Second Quarter 2023 10-Q the Week of August 7 and Expects to Host a Conference Call the Following Week
-
Delcath Systems Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Delcath Systems Appoints Vojislav Vukovic as Chief Medical Officer
-
Delcath Systems Announces Sandra Pennell as Senior Vice President of Finance
-
Delcath Systems Provides Business Update and Reports Preliminary First Quarter 2023 Financial Results
-
Delcath Systems to Participate in the Lytham Partners Spring 2023 Investor Conference
-
Delcath Systems to Host First Quarter 2023 Results
-
Delcath Systems Announces Resumption of Interest-Only Period for Company's Debt Facility
-
Delcath Systems Announces Closing of Private Placement of up to $85 Million
-
Delcath Systems Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
-
Delcath Systems Announces up to $85 Million Financing
-
Delcath Systems, Inc. Announces FDA Acceptance of New Drug Application Resubmission of Hepzato Kit with a PDUFA Date of August 14, 2023
-
Delcath Announces Rotation of the Board of Directors Chairmanship; John R. Sylvester Appointed New Chairman as Company Prepares for US Commercial Launch
-
Delcath Systems Announces New Drug Application Resubmission for HEPZATO Kit
-
Delcath Systems to Participate at the BTIG MedTech, Digital Health, Life Sciences & Diagnostic Tools Conference on February 14 to 16
-
Delcath Systems Announces Updated Results from CHOPIN Phase 1b Trial Published in Cardiovascular and Interventional Radiology
-
Delcath Systems Announces Inducement of Grant Under NASDAQ Listing Rule 5635(C)(4)
-
Delcath Systems Closes Private Placement of $6.2 Million
-
Delcath Systems Announces Private Placement of $6.2 Million
-
Results of a Single Center Study on Delcath's CHEMOSAT® Hepatic Delivery System In the Treatment of Cholangiocarcinoma Published in the Journal Clinical & Experimental Metastasis
-
Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Delcath Systems Reports Third Quarter 2022 Results and Provides Business Update
Back to DCTH Stock Lookup
